NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
NFE2L2 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
NFE2L2 mutation	Solid Tumor	NFE2L2 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
NFE2L2 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
NFE2L2 overexpression	Hepatocellular Cancer	NFE2L2 overexpression	Hepatocellular Cancer	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3
NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
NFE2L2 overexpression	Acute Myelogenous Leukemia	NFE2L2 overexpression	Acute Myelogenous Leukemia	cytarabine Resistant: D – Preclinical cytarabine Resistant : D	cytarabine Resistant: D – Preclinical cytarabine Resistant : D
NFE2L2 mutation + CTNNB1 mutation	Hepatocellular Cancer	NFE2L2 mutation + CTNNB1 mutation	Hepatocellular Cancer	everolimus Sensitive: D – Preclinical everolimus Sensitive : D	everolimus Sensitive: D – Preclinical everolimus Sensitive : D

NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)

Associations(14)

Associations
(14)